MedTrace Logo

L-Arginine and Sickle Cell Disease

NCT01142219 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-06-11

No results posted yet for this study

Summary

One of the main problems in sickle cell disease is the decreased bioavailability of nitric oxide and arginine. This study was designed to assess if treating sickle cell disease patients with L-arginine would improve pulmonary arterial pressure and other aspects.

Conditions

Interventions

DRUG

L-arginine

L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.

DRUG

Placebo

Mannitol was administered orally at a dose of 01 g/kg/day for six months.

Sponsors & Collaborators

  • Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)

    collaborator UNKNOWN

  • Associação de Amigos da Hematologia (HEMOAMIGOS)

    collaborator UNKNOWN

  • Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine)

    collaborator UNKNOWN

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-01-31
Completion
2009-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01142219 on ClinicalTrials.gov